The US Federal Trade Commission (FTC) has accepted a proposed consent order, agreeing certain asset divestments, which concludes the FTC’s review of the proposed combination of Netherlands-incorporated generics drugmaker Mylan (Nasdaq: MYL) and US pharma giant Pfizer’s (NYSE: PFE) Upjohn Business.
The parties have now obtained all required antitrust clearances for the proposed transaction, the companies said.
The Commission vote to issue the complaint and accept the proposed consent order for public comment was 3-2.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze